Researchers from the Cancer Science Institute of Singapore at the National University of Singapore (NUS), have achieved breakthroughs in understanding relapse after chemotherapy for a type of cancer known as diffuse large B-cell lymphoma (DLBCL).
FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing
The FDA rejected Rocket Pharmaceuticals’ gene therapy for leukocyte adhesion deficiency-I (LAD-I), requesting “limited additional” manufacturing information. The company announced the … Sign up to
June 29, 2024